Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia

Therapeutic Advances in Hematology
Zenghui LiuYang Xiao

Abstract

The application of haploidentical hematopoietic stem cell transplantation (HSCT) with mesenchymal stem cell (MSC) infusion as a treatment regimen for severe aplastic anemia (SAA) has been reported to be efficacious in single-arm trials. However, it is difficult to assess without comparing the results with those from a first-line, matched-sibling HSCT. Herein, we retrospectively reviewed 91 patients with acquired SAA. They received HSCT from haploidentical donors combined with MSC transfer (HID group). We compared these patients with 103 others who received first-line matched-sibling HSCT (MSD group) to evaluate relative treatment efficacy. Compared with the patients in the MSD group, those in the HID group presented with higher incidences of grades II-IV and III-IV acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) (p < 0.05). However, the incidence of myeloid and platelet engraftment, graft failure, poor graft function, and extensive cGvHD were comparable for both groups. The median follow-up was 36.6 months and the 3-year overall survival rate was similar for both groups (83.5% versus 79.1%). Univariate and multivariate analyses revealed that time intervals greater than 4 months from diagnos...Continue Reading

References

Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Per LjungmanCarlos Paya
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hillard M LazarusAndrea Bacigalupo
Apr 23, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J F LacerdaJ M F Lacerda
Dec 21, 2005·Blood Reviews·Francesco DazziIrene Roberts
May 30, 2006·Transplantation·Olle RingdénKatarina Le Blanc
Nov 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Robb FriedmanHans Klingemann
Jan 1, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jonas MattssonRainer Storb
May 13, 2008·Lancet·Katarina Le BlancUNKNOWN Developmental Committee of the European Group for Blood and Marrow Transplantation
Jul 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mei GuoHuisheng Ai
Sep 29, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Neal S YoungJudith C W Marsh
Dec 12, 2012·Bone Marrow Transplantation·R OlssonO Ringden
Nov 17, 2015·British Journal of Haematology·Sally B KillickUNKNOWN British Society for Standards in Haematology
Jun 29, 2016·British Journal of Haematology·Lan-Ping XuXiao-Jun Huang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.